May 25, 2017 · Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia linked to disseminated microvascular platelet rich-thrombi.

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi.

Apr 7, 2023 · Thrombotic thrombocytopenic purpura (TTP) is a type of microangiopathic hemolytic anemia that classically has been characterized by the pentad of fever, thrombocytopenia, hemolytic anemia, renal dysfunction, and neurologic dysfunction.

Nov 30, 2018 · In this article, we review recent evidence on the epidemiology, natural history, and clinical manifestations of TTP as well as the utility of ADAMTS13 laboratory testing, and we suggest an evidence-based approach to the diagnosis of TTP that integrates clinical and laboratory information.

May 4, 2006 · In the Oklahoma Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome (TTP–HUS) Registry, 10 percent of patients with an initial diagnosis of idiopathic thrombotic thrombocytopenic ...

Apr 6, 2017 · Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is characterized by the concomitant occurrence of often severe thrombocytopenia, microangiopathic haemolytic...

Sep 27, 2023 · Thrombotic thrombocytopenic purpura (TTP) is a rare microangiopathic hemolytic anemia that causes blood clots in small blood vessels. TTP is characterized by fever, hemolytic anemia, thrombocytopenia, and renal and neurologic dysfunction.

Thrombotic thrombocytopenic purpura (TTP), a potentially fatal clinical syndrome, is primarily caused by autoantibodies against the von Willebrand factor (VWF)-cleaving metalloprotease ADAMTS13.

Dec 1, 2021 · As our understanding of this devastating condition has evolved, a need for updates has emerged in this increasingly complex setting. In this review, we summarize novel data regarding the pathophysiology, clinical diagnosis, acute management, long-term follow up and emerging therapies for TTP.

This article reviews the neurologic complications of TTP and provides neurologists with strategies for diagnosis and treatment. 1.1. TTP complicated with cerebrovascular disease. The pathophysiological basis of TTP is the deficiency of ADAMTS13 protease which cleaves the Von Willebrand factor (VWF) polymer.